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Abstract 
Eukaryotic translation elongation factor 1 gamma, 
alias eEF1G, is a protein that plays a main function 
in the elongation step of translation process but also 
covers numerous moonlighting roles. Considering its 
importance in the cell it is found frequently 
overexpressed in human cancer cells and thus this 
review wants to collect the state of the art about 
EEF1G, with insights on DNA, RNA, protein 
encoded and the diseases where it is implicated. 
Keywords 
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Identity 
Other names: EF1G, GIG35, PRO1608, EEF1γ, 
EEF1Bγ 
HGNC (Hugo): EEF1G 
Location: 11q12.3 
Figure. 1. Splice variants of EEF1G.  The figure shows the locus on chromosome 11 of the EEF1G gene and its splicing variants 
(grey/blue box). The primary transcript is EEF1G-001 mRNA (green/red box), but also EEF1G-201 variant is able to codify for a 
protein (reworked from https://www.ncbi.nlm.nih.gov/gene/1937; http://grch37.ensembl.org; www.genecards.org) 
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Variant Name RefSeq (1) Transcript ID Exons Type 
Lenght 
(bp) 
RefSeq (2)  
Lenght 
(aa) 








- ENST00000532986.1 5 
Processed 
transcript 




- ENST00000524420.5 5 
Processed 
transcript 
557 - - 
5 EEF1G-201 AK300203.1 - 10 Protein coding 1631 BAG61974.1 487 




EEF1G (Eukaryotic Translation Elongation Factor 1 
Gamma) is a protein coding gene that starts at 
62,559,601 nt and ends at 62,573,988 nt from qter 
and with a length of 14388 bp. The current reference 
sequence is NC_000011.10 and contains 10 exons. It 
is proximal to the nucleotidyl transferase TUT1 
(terminal uridylyl transferase 1) gene and to the 
AHNAK nucleoprotein gene. Inside the nucleotidic 
sequence of EEF1G there is also a short non-coding 
sequence of the microRNA MIR6747 that starts 
from 62567011 bp and ends at 62567071 bp and is 
61 bp long. Around the genomic locus of EEF1G 
take place different promoter or enhancer 
transcriptional elements. Two strong elements are 
closer to the sequence of EEF1G gene and are 
located at -1.4 kb and at +2.4 kb respectively and 
have a high influence of different kind of genes in 
their proximity, such as EEF1G1 and TUT1. 
Transcription 
EEF1G mRNA is 1446 bp long with a reference 
sequence reported in GeneBank as NM_001404.5. 
The 5'UTR sequence is not very long and counts 49 
nt. The CDS is extended from 50 to 1363 nt, while 
the 3'UTR starts from 1364 until 1446 nt. EEF1G is  
expressed ubiquitously in human tissues with a 
different expression level in relation to the specific 
tissue type. Minor expression levels are reported for 
brain, liver, lung, pancreas, salivary glands and testis 
while on the contrary a significantly higher 
expression level is found in the ovary (Fagerberg et 
al., 2014). Five splice variants for EEF1G were 
observed (Table.1): the main reference variant is 
EEF1G-001 and the others are EEF1G-002, EEF1G-
003, EEF1G-004 and EEF1G-201 (Figure.1). Only 
two of which codify for a protein, i.e. EEF1G-001 
and EEF1G-201, while the others are non-coding 
RNA sequences (ncRNAs), classified as processed 
transcripts, i.e. nucleotide sequences that do not 
contain an open reading frame (ORF) and 
alternatively spliced transcripts, i.e. retained intron 
sequences. Furthermore, there is a potential 
readthrough with the inclusion of TUT1 gene. 
Pseudogene 
According to Entrez Gene, the analysis of the human 
genome revealed the presence of nine pseudogenes 
for EEF1G (Table.2) classified as processed 
pseudogenes and probably originated by 
retrotransposition. If these elements have any 
regulatory roles on the expression of the respective 
gene as described for others (Hirotsune et al., 2003), 
is only speculation in the absence of experimental 
evidence. 
 
Gene Gene  name Gene ID RefSeq Locus Location Start End Lenght (nt) 
EEF1GP1 EEF1G1 Pseudogene 1 646837 NC_000007.14 Chromosome 7 7q31.33 125033433 125035389 1957 
EEF1GP2 EEF1G1 Pseudogene 2 100130260 NC_000005.10 Chromosome 5 5q32 147922182 147923422 1241 
EEF1GP3 EEF1G1 Pseudogene 3 651628 NC_000003.12 Chromosome 3 3p22.1 40596122 40597519 1398 
EEF1GP4 EEF1G1 Pseudogene 4 100129403 NC_000003.12 Chromosome 3 3q26.1 161324837 161326238 1402 
EEF1GP5 EEF1G1 Pseudogene 5 642357 NC_000023.11 Chromosome X Xq23 115702791 115704195 1405 
EEF1GP6 EEF1G1 Pseudogene 6 100421733 NC_000006.12 Chromosome 6 6q16.1 96750800 96751728 929 
EEF1GP7 EEF1G1 Pseudogene 7 645311 NC_000001.11 Chromosome 1 1p32.3 52573115 52573818 704 
EEF1GP8 EEF1G1 Pseudogene 8 391698 NC_000004.12 Chromosome 4 4q28.2 129903001 129904244 1244 
LOC729998 EEF1G1 Pseudogene 9 729998 NC_000007.14 Chromosome 7 7q33 133034515 133035940 1426 
Table.2 EEF1G pseudogene (reworked from https://www.ncbi.nlm.nih.gov/gene/1937) 
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Figure.2 eEF1G protein structure analysis.  (1) Primary structure of eEF1G with emphasis on its three principal domains 
(reworked from Achilonu et al.,2014; https://www.uniprot.org; https://www.proteomicsdb.org; https://prosite.expasy.org); (2) 




Are described two isoforms for eEF1G and it is 
shown that this protein has a glutathione S-
transferase activity. In addition, eEF1G is a 
structural constituent of a greater protein complex 
that is in relation to the ribosome and plays a role in 
the elongation step of protein synthesis. 
Description 
The eukaryotic elongation factor 1-gamma (alias 
eEF1G, eEF1γ, heEF1γ, eEF1Bγ) is a subunit of the 
macromolecular eukaryotic elongation factor-1 
complex (alias eEF1, also called eEF1H), a high-
molecular-weight form made up of an aggregation of 
different protein subunits: eEF1A (alias eEF1α), 
eEF1B (alias eEF1 β, eEF1Bα, eEF1B2), eEF1G, 
eEF1D (alias eEF1δ, eEF1Bδ) and valyl t-RNA 
synthetase (valRS). eEF1H protein complex plays 
central roles in peptide elongation during eukaryotic 
protein biosynthesis, in particular for the delivery of 
aminoacyl-tRNAs to ribosome mediated by the 
hydrolysis of GTP. In fact, during the translation 
elongation step, the inactive GDP-bound form of 
eEF1A (eEF1A-GDP) is converted to its active 
GTP-bound form (eEF1A-GTP) by eEF1BGD 
complex-mediated GTP hydrolysis so it acts as a 
guanine nucleotide exchange factor (GEF), 
regenerating eEF1A-GTP for the successive 
elongation cycle. The physiological role of eEF1G in 
the translation context is still not well defined, 
however eEF1G seems to be necessary for this 
nucleotide exchange. Studies did not confirm its 
direct involvement in this process but it is supposed 
that it may stimulate the activity of eEF1B and 
guarantee stability to entire eEF1H complex (Ejiri, 
2002; Mansilla et al., 2002). In addition, studies 
revealed that eEF1G sequence does not contain any 
consensus sequence for ATP or GTP binding 
(Maessen et al., 1987).  
There are known two isoforms produced by 
alternative splicing: the isoform 1 (RefSeq 
NP_001395.1; UniParc, P26641-1), that has been 
chosen as the canonical sequence, is formed by 437 
residues and has an overall molecular weight of 
50.12 kDa, while the isoform 2 (RefSeq 
BAG61974.1; UniParc, P26641-2) is 487 amino 
acids long with 56.15 kDa of molecular weight.  The 
sequence of this isoform differs from the canonical 
sequence for the substitution of the first four amino 
acids (MAAG) by the insertion of other fifty residues 
(MAERWVAPAVLRRARFASTFFLSPQIYAHKD
GDLRSAFFILSFKRGEFIPFLNW) with the 
creation of an alternative amino acid sequence (Ota 
et al., 2004). No experimental data or other studies 
were performed for this isoform, so its biological 
role is totally unknown.  
eEF1G shown hydrophobic properties, has a 
relatively high isoelectric point (pI ≈ 7) (van Damme 
et al., 1991) and the analysis of its primary and 
secondary structures revealed some interesting 
characteristics. In fact, it is a multi-domain protein 
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which consists of three main domains: from the 
amino to carboxyl half terminal there are a 
glutathione S-transferase (GST)-like N-terminus 
domain (NT-eEF1G), a glutathione S-transferase 
(GST)-like C-terminus domain (CT-eEF1G) and a 
conserved C-terminal domain (CD-eEF1G) 
(Achilonu et al.,2014). NT-eEF1G and CT-eEF1G 
domains show a homology to the theta class of 
glutathione S-transferases (GSTs) (Koonin et al., 
1994; Janssen and Möller, 1988).  
The NT-eEF1G domain of eEF1G, by using 
secondary structure prediction algorithms, seems to 
have a predominant α-helix secondary structure 
(Achilonu et al.,2014) and it was demonstrated that 
interacts directly with the N-terminal domain of 
eEF1B (van Damme et al., 1991) and also with the 
N-terminal domain of eEF1D in independent manner 
(Cao et al., 2014; Mansilla et al., 2002; Janssen et al., 
1994), although different interactional models were 
proposed (Le Sourd et al., 2006; Jiang et al.,2005; 
Sheu and Traugh, 1999; Minella et al., 1998). It does 
not seem to have a direct interaction with other 
eEF1H elements.  
In addition, the presence of an enzymatically active 
GST element could be involved in detoxification of 
oxygen radicals and the over-expression of eEF1G 
in cancer cells could influence their response to 
oxidative stress and their aggressiveness (Koonin et 
al., 1994).  
The calculated secondary structure of the CT-eEF1G 
domain of eEF1G shows both α-helix and  β-strand 
secondary structure elements (Achilonu et al.,2014) 
and does not interact with eEF1B but instead is the 
candidate domain to has transient interactions with 
other proteins or cell structures.  
The CD-eEF1G domain of eEF1G seems to be 
mostly in α-helix secondary structure with few β-
strands (Achilonu et al.,2014) and currently it does 
not show particular elements or interactions.  
It is interesting that eEF1G shows two internal 
repeats of eight amino acids (VFGEXNXS) at 
positions 35 - 42 and 355 - 362 respectively, that are 
located in its amino-terminal and carboxy-terminal 
halves.  
The roles of these two octapeptides are still unknown 
even if they could cover the function of binding-sites 
(van Damme et al., 1991; Maessen et al., 1987).  
eEF1G seems to have in human cells a dimeric 
nature, forming homodimers, while in rabbit shows 
a trimeric nature and in yeast was observed that it 
acts as a monomer (Achilonu et al.,2014; Koonin et 
al., 1994). Furthermore, it has hydrophobic 
properties that enable it to attach to membranes 
(Mansilla et al., 2002).  
eEF1G interacts mainly with EEF1B2 and EEF1D, 
even if other interactions are documented in protein  
databases and in literature, i.e. with the histidyl-
tRNA synthetase (HARS), leucyl-tRNA synthetase 
(LARS), cysteine-tRNA synthetase (CARS), leucine 
zipper putative tumor suppressor 1 (LZTS1), enoyl-
CoA hydratase 1(ECH1), plasminogen receptor 
(PLGRKT), small ubiquitin-related modifier 2 
(SUMO2), ATP-binding cassette sub-family C 
member 9 ( ABCC9), tripartite motif containing 55 
(TRIM55), E3 ubiquitin-protein ligase (TRIM63), 
interleukin enhancer binding factor 2 (ILF2), 
vascular cell adhesion protein 1 (VCAM1), 
eukaryotic translation elongation factor 1 delta 
pseudogene 3 (EEF1DP3), RNA-binding protein 6 
(RBM6) (HuRI database - 
http://interactome.baderlab.org/), ATP-dependent 
DNA helicase Q5 (RECQL5) and fasciculation and 
elongation protein zeta 1 ( FEZ1)(Ishii et al., 2001) 
although the nature of these interactions are poorly 
understood.  
Post-translational modifications.  Some post-
translational modifications are observed, such as 
phosphorylation, acetylation and S-nitrosylation.  
1) Phosphorylation:  it was demonstrated that 
eEF1G is a target of the kinases, in particular the cell 
cycle protein kinase CDK1 /cyclin B (Le Sourd et 
al., 2006; Mansilla et al., 2002).  
There are at least four positions for phosphorylation: 
two on threonine residues (T43, T230) and two on 
serine residues (S286, S406) (Olsen et al., 2010; 
http://hprd.org).  
It is assumed that these phosphorylations play a 
regulatory role, but their exact functional 
significance is poorly understood.  
2) Acetylation:  there are three positions for 
acetylation on lysine residues (K132, K147, K434) 
(Choudhary et al., 2009; http://hprd.org).  
3) S-nitrosylation:  there is one most probable 
position for S-Nitrosylation on a cysteine residue 
(C194) (Han and Chen, 2008; http://hprd.org). 
Expression 
EEF1G mRNA is expressed widely as previous 
reported while the presence of eEF1G protein in 
human tissues shows unexpected differences i.e. 
higher levels of protein are observed in cerebellum, 
hippocampus, esophagus, stomach, small intestine 
and pancreas while its low expression levels are 
reported in oral mucosa, bronchus, lung, parathyroid 
glands, adrenal glands, smooth muscle, prostate and 
urinary bladder.  
No protein presence is found in bone marrow, heart 
muscle, kidney, liver and skeletal muscle (Fagerberg 
et al., 2014). Furthermore was revealed the presence 
of the protein both in the human physiological 
secretions (cerumen, saliva, milk, urine, seminal 
plasma) and in pathological intercellular fluids 
(ascites) (https://www.proteomicsdb.org).  
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Figure 3. Translation elongation mechanism.  The active form of eukaryotic elongation factor 1 (eEF1A) in complex with GTP 
delivers an aminoacylated tRNA to the A site of the ribosome. Following the proper codon-anticodon recognition the GDP is 
hydrolyzed and the inactive eEF1A-GDP is released from the ribosome and then it is bound by eEF1B2GD complex forming the 
macromolecular protein aggregate eEF1H. eEF1H is formed previously by the binding of three subunits: eEF1B2, eEF1G and 
eEF1D. This complex promotes the exchange between GDP and GTP to regenerate active form of eEF1A (reworked from 
Dongsheng et al., 2013; Ejiri, 2002; Riis et al, 1990; https://reactome.org) 
 
The expression pattern in cell lines tested for its 
presence is similar and without significantly 
differences except in one study that revealed a higher 
expression in human embryonic kidney HEK293 cell 
line and in human liver hepatocellular carcinoma 
HepG2 cell line (Cao et al, 2014). 
Localisation 
eEF1G is located mostly in the cytoplasm where 
forming a gradient from the nucleus to the periphery 
of the cell, but some studies find it also in cellular 
nucleus, nucleolus, mitochondria and in relation with 
endoplasmic reticulum and plasma membrane (Cho 
et al., 2003; Minella et al., 1996; Sanders et al., 
1996). It was reported also its localization in 
extracellular exosomes (Principe et al., 2013). 
Function 
eEF1G shows canonical functions and multiple non-
canonical roles (moonlighting roles) inside the cell.  
 Canonical function:  eEF1G binds to eEF1B and 
eEF1D and is supposed that its primary role may be 
to ensure the proper scaffolding and stability of its 
binding partners in the eEF1BDG macromolecular 
complex and then it could anchors the entire EF1H 
complex to the endoplasmic reticulum together with 
the ribosome (Mansilla et al., 2002; Janssen et al., 
1994). However, the complete significance of the 
role of human eEF1G remains unknown and needs 
to be more studied.  
Non-canonical roles: eEF1G has shown to interact 
with cytoskeleton, RNA polymerase II, TNF 
receptor-associated protein 1 (TRAP1) and 
membrane-bound receptors. In addition, it was 
observed that it has mRNA binding properties and it 
is a positive regulator of NF-kB signaling pathway.  
 1) eEF1G and cytoskeleton:  it was discovered that 
eEF1G is a structural component of the cytoskeleton 
(Coumans et al., 2014), in fact it can bind both 
keratin intermediate filaments (Kim et al., 2017) and 
the tubulin (Janssen and Möller, 1988). This 
suggests that it may have an influence on 
cytoskeletal architecture, cell morphology and 
motility, but these implications and the roles of these 
bindings are still need to clarify.  
 2) eEF1G and interaction with RNA polymerase 
II:  it physically interacts with RNA polymerase II 
(pol II) core subunit 3 ( POLR2C), both in isolation 
and in the context of the holo-enzyme (Corbi et al., 
2010).  
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 3) interaction between eEF1G and TNF 
receptor-associated protein 1 (TRAP1):  TRAP1 
is the main mitochondrial member of the heat shock 
protein (HSP) 90 family and it was revealed that 
there is an interaction between this protein and some 
members of eEF1H complex, including eEF1G.  
The role of the interaction between eEF1G and 
TRAP1 is related to the translational control 
(Matassa et al., 2013) and maybe also in the 
protection to oxidative stress (Pisani et al., 2016).  
 4) eEF1G and membrane-bound receptors 
(dopamine D3 receptor):  it was observed that there 
is an interaction between eEF1G and dopamine D3 
receptor ( DRD3) and that they have a co-
localization on the plasma membrane.  
This interaction involve also eEF1B subunit after its 
protein kinase-mediated phosphorylation on its 
serine residues.  
eEF1G acts as a bridge for the relation between 
eEF1B and DRD3 and these three factors together 
forming a new macromolecular complex on the 
plasma membrane that obviously play some roles 
even if its functional meaning is still understood 
(Cho et al., 2003).  
 5) mRNA binding properties:  the presence of 
eEF1G was detected on the genomic locus 
corresponding to the promoter region of human 
vimentin gene VIM and this permits to suppose that 
eEF1G regulates vimentin gene by contacting both 
pol II and the vimentin promoter region.  
In addition was shown that it can bind to 3'UTR of 
vimentin mRNA and so it can shuttling/nursing the 
vimentin mRNA from its gene locus to its 
appropriate cellular compartment for translation. In 
fact, depletion of eEF1G causes the incorrect 
compartmentalizing of the vimentin protein and 
seriously compromise cellular shape and 
mitochondria localization (Corbi et al., 2010). 
Furthermore, was shown that eEF1G can bind also 
AATF (Che-1) and  transcription and their promoter 
regions (Pisani et al., 2016).  
 6) regulation of NF-kB signaling pathway:  
eEF1G can binds to the CARD domain of 
mitochondrial antiviral-signaling protein ( MAVS) 
and thus significantly promotes the activities of 
transcription factor NF-kB functioning as its positive 
regulator.  
The discover offers a new regulating mechanism of 
the antiviral responses that promotes the downstream 
pro-inflammatory cytokines CXCL8 (interleukin-8 
(IL8)) and interleukin-6 ( IL6) (Liu et al., 2014). 
Homology 
eEF1G is highly and abundant conserved in many 
species, with sometimes the lack of NT-eEF1G 
domain. The homology for eEF1G protein between 
species is reported in Table.3  
Mutations 
The great number of mutations in the genomic 
sequence or in the amino acid sequence for EEF1G 
was discovered in cancer cells that are obviously 
genetically more unstable respect normal cells. The 
genomic alterations observed include the formation 
of novel fusion genes as EBF3/EEF1G, 
EEF1G/ALK, EEF1G/ENG, EEF1G/GFAP, 
EEF1G/MTA2, EEF1G/MYH9, EEF1G/NXF1, 
EEF1G/OOEP [t(6;11)(q13;q12) EEF1G/OOEP], 
EEF1G/PPP6R3 [t(11;11)(q12;q13) 
EEF1G/PPP6R3], EEF1G/TOX2, EEF1G/UBXN1, 
ETFB/EEF1G, HNRNPUL2/EEF1G, 
IGHG1/EEF1G, IGHM/EEF1G and 
NCEH1/EEF1G (Klijn et al., 2015; 
http://atlasgeneticsoncology.org/Bands/11q12.html; 
http://quiver.archerdx.com), however there are no 
experimental data yet to understand the 
repercussions on cellular behavior and so the 
implications in cancer of these fusion genes are 
unclear.  
There is one chromosomic translocations with 
production of a novel fusion gene that is more 
investigated and it is t(2;11)(p23;q12.3) 
EEF1G/ALK. 
Organism (1)   Organism (2)   Symbol    
Similarity 
(%) 
Human   H.sapiens   eEF1G   100 
Chimpanzee   P.troglodytes   eEF1G   100 
Gorilla   
G.gorilla 
gorilla   
eEF1G   99 
Cat   Felis catus   eEF1G   99 
Mouse    M.musculus   eEF1G   98 
Rat   R.norvegicus   eEF1G   98 
Zebrafish   D.rerio   eEF1G   75 
Drosophila   D.melanogaster   Ef1gamma   58 
 Caenorhabditis    C.elegans   F17C11.9   52 
Yeast   S.cerevisiae   TEF4   38 




High expression levels of eEF1G are observed in 
many cancer types and, clinically, the 
overexpression of EEF1G was correlated with a poor 
or better prognosis of cancers in relation to a specific 
cancer type (Hassan et al., 2018). It is unclear if 
EFF1G overexpression concurs to the tumoral 
process or it is a simply consequence and when it 
occurs the mechanism of overexpression of EEF1G 
is not known (Frazier et al., 1998). In addition, was 
observed a few translocations with creation of fusion 
genes with other proteins in some cancer cell types. 
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t(2;11)(p23;q12.3) EEF1G/ ALK 
Anaplastic lymphoma kinase (ALK)-positive 
anaplastic large cell lymphoma (ALCL) is 
characterized by many genomic aberrations and 
chromosomal rearrangements that make the cellular 
caryotype much complicated. There are revealed 
many ALK aberrations and rearrangements with 
several variant of partner fusion genes (van der 
Krogt et al., 2017; van Krieken, 2017). 
Prognosis 
The prognosis is very poor, in fact patients 
expressing EEF1G/ALK fusion gene have shown an 
unfavorable clinical course with fatal outcome. 
Hybrid/Mutated gene 
It was observed in some ALK+ ALCL pediatric 
patients the presence of an in-frame fusion transcript 
between an intronic region among exons 8 and 9 of 
EEF1G with the middle part of exon 20 of ALK. The 
resulting novel fusion chimeric gene 5'EEF1G / 
3'ALK was revealed to be a coding-gene (van der 
Krogt et al., 2017). On the contrary, other authors 
found a fusion gene originated by the fusion of exon 
6 of EEF1G with the exon 20 of ALK (Palacios et 
al., 2017). 
Abnormal protein 
The chimeric protein eEF1G/ALK is active and has 
the complete GST-like N-terminal domain and part 
of the CT domain of EEF1G fused to the complete 
intracellular protein tyrosine kinase (PTK) domain 
of ALK. Cytoplasm is the subcellular localization for 
this chimera (van der Krogt et al., 2017; van Krieken, 
2017) but its biological activities, its oncogenic 
potential and its roles in proliferation and cancer 
aggressiveness are still poor understood although it 
is supposed that eEF1G/ALK fusion protein has a 
cell-transforming activity due to the activation of 
ALK kinase (Palacios et al., 2017). 
Acute myeloid leukemia (AML) 
Acute myeloid leukemia (AML) is the most common 
and severe form of acute leukemia diagnosed in 
adults. EEF1G was find over-expressed in AML-M1 
and AML-M2 samples from adult patients 
(Handschuh et al, 2017). 
Brain and central nervous system 
(CNS) cancer 
EEF1G mRNA levels are significantly upregulated 
in brain and CNS cancers. It is found over-expressed 
in glioblastoma and glioma, however higher levels 
of expression are found also in low-risk patients, so 
this can predict favourable survival outcome (Hassan 
et al., 2018). On the contrary, another study observed 
a down-regulation of EEF1G in glioblastoma 
multiform (Vastrad and Vastrad, 2018). 
Breast Cancer 
High expression of EEF1G is observed in breast 
cancer cells and also in peripheral blood samples of 
breast cancer patients respect to healthy subjects 
(Coumans et al., 2014 ; Aarøe et al., 2010), although 
other studies shown that it is down-regulated and 
instead an increase of EEF1G transcript levels have 
positive correlation with distant metastasis free 
survival (DMFS) and relapse free survival (RFS) and 
so seems that over-expression of EEF1G is 
correlated with a significantly good prognosis in 
luminal A subtype (Hassan et al., 2018). EEF1G is 
considered a negative marker for ERPR positive 
breast cancer (Tyanova et al., 2016). 
Cervical carcinoma 
EEF1G is observed to be highly expressed in 
cervical intraepithelial neoplasia (Shadeo et al., 
2008). 
Colorectal cancer 
EEF1G is over-expressed by twofold to tenfold in a 
great percentage of colorectal adenomas and by 
twofold to 26-fold in the colorectal carcinoma 
compared to normal tissue and also its relative 
protein eEF1G was found over-expressed, 
suggesting that early modification of its expression 
levels occurs and so it may be a useful marker for the 
detection of an early stage of tumor development 
(Frazier et al., 1998; Ender et al., 1993; Chi et al., 
1992 ; Mathur et al., 1988).  
The overexpression of eEF1G in the colorectal 
cancers seems to be not due to gene amplification, 
genome rearrangements or an increase in the number 
of cycling cells (Frazier et al., 1998).  
Interestingly is the positive correlation that was 
found in this cancer type between co-expression 
levels of TNF Receptor Associated Protein 1 
(TRAP1) and eEF1G: the majority of the TRAP1-
positive tumors exhibit an upregulation of eEF1G 
and, on the contrary, tumors with low expression of 
TRAP1 also exhibit low levels of expression of 
eEF1G (Matassa et al., 2013). This evidence may 
have an interesting significance in the increase or 
decrease of tumor aggressiveness and in the 
development of new anti-cancer strategies. 
Moreover, the reduction of expression levels of 
eEF1G in high-risk patients can predict poor survival 
(Hassan et al., 2018). 
Esophageal carcinoma 
eEF1G is overexpressed in only a minimum part of 
esophageal carcinoma tissues examined respect 
normal counterpart and there is not any evidence 
between its expression level and the growth rates of 
tumor.  
However, cancers over-expressing eEF1G show 
more aggressiveness and show a more metastatic 
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behavior respect cancer cells that not overexpressing 
this gene.  
On the contrary, eEF1G is over-expressed in all 
esophageal cancer cell lines tested (Frazier et al., 
1998; Mimori et al., 1996). 
Gastric cancer 
EEF1G was found significantly overexpressed in 
low-grade gastric adenomas (Takenawa et al., 2004)  
while on the contrary in another study was observed 
that its expression level is down-regulated in gastric 
cancer cells and that higher levels of its expression 
could predict a poor overall survival (OS) and first 
progression (FP)(Hassan et al., 2018). Other authors 
found not only an overexpression of this gene in 
gastric carcinomas but also that tumors 
overexpressing EEF1G have more vascular 
permeation/angiogenesis than the others (Frazier et 
al., 1998; Mimori et al., 1995). This evidence is very 
significant and could be suppose that an 
overexpression of EEF1G may be compatible with 
more aggressiveness of the gastric cancer cells that 
show a higher expression levels for this protein. 
Head and neck squamous cell 
carcinoma 
mRNA levels of EEF1G are downregulated in tumor 
tissues than normal but in high-risk patients these 
levels become significantly higher (Hassan et al., 
2018). 
Kidney cancer 
EEF1G expression level is significantly upregulated 
in kidney clear cell carcinoma.  
These high expression levels may predict better 
survival in low-risk patients (Hassan et al., 2018). 
Liver cancer 
mRNA levels of EEF1G are significantly 
upregulated in liver cancer cells respect normal ones 
and this may predict worse survival in high-risk 
patients (Hassan et al., 2018 ; Wang et al., 2009).  
In particular, mRNA expression levels of EEF1G 
remain at basal levels in a well to moderately 
differentiated (W/M-) primary human hepatocellular 
carcinoma (HCC), while they are further up-
regulated in moderately to poorly differentiated 
(M/P-) HCC according their histological grading 
(Shuda et al, 2000).  
In contrast, in vitro studies on cell cultures of HBV- 
or HCV-HCC have shown in most cases a down-
regulation of EEF1G expression levels (Yoon et al., 
2006). 
Lung cancer 
The expression levels of EEF1G are slightly higher 
in lung cancer cells respect normal ones and this lead 
to poor overall survival (OS) and first progression 
(FP) in lung cancer and thus are significantly 
correlated with worse survival outcome in lung 
adenocarcinoma (Hassan et al., 2018).  
In addition, from a preliminary study was observed 
an EEF1G differential expression between stage I 
from stage II lung squamous carcinoma: in the 
second EEF1G has high expression levels and this 
may be one of the causes of the increase of grade of 
malignancy.  
However, other investigations are needed to confirm 
this preliminary evidence (Wang et al., 2018). 
Hybrid/Mutated gene 
In squamous cell carcinoma of the lung was 
discovered the fusion gene t(11;11)(q12;q13) 
EEF1G/PPP6R3 (Hammerman et al., 2012). 
Lymphoma 
EEF1G is significant overexpressed in Burkitt's 
lymphoma and diffuse large B-Cell Lymphoma 
(Hassan et al., 2018). 
Hybrid/Mutated gene 
In acute lymphoblastic leukemia/lymphoblastic 
lymphoma was discovered the fusion gene 
t(6;11)(q13;q12) EEF1G/OOEP (Atak et al., 2013) 
and the presence of translocation t (2;11)(p23; q12.3) 
EEF1G/ALK was observed in pediatric anaplastic 
lymphoma kinase (ALK)-positive anaplastic large 
cell lymphoma (ALCL). 
Melanoma 
EEF1G gene is relevantly co-expressed with other 
genes in  melanoma subtype 6 (Gan et al., 2018). 
Hybrid/Mutated gene 




EEF1G is significant overexpressed in myeloma 
cells in the bone marrow of multiple myeloma 
patients (Sariman et al., 2019). 
Ovarian cancer 
High expression of EEF1G is found in ovarian 
cancer and this may predict a better overall survival 
(OS) and progression-free survival (PFS)(Hassan et 
al., 2018). 
Pancreatic cancer 
From collected data seem to be no significantly 
difference between the expression levels of EEF1G 
in pancreatic cancer cells compared with normal 
ones (Hassan et al., 2018), however in some studies 
were evidenced that EEF1G is over-expressed 
(Frazier et al., 1998 ; Chi et al., 1992 ; Lew et al., 
1992). The presence of a higher level of its 
expression may become a marker of poor 
survivability for high-risk patients (Hassan et al., 
2018). 
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Pleomorphic adenoma of the human 
parotid gland 
There is one study in which were found down-
expressed levels for this gene (Mutlu et al., 2017). 
Prostate cancer 
A significant overexpression of EEF1G is seen in 
prostate tumor tissues although this evidence seems 
not to affect the survival outcomes (Hassan et al., 
2018). Remarkable is the discovery of presence of 
eEF1G in exosomes contained in expressed prostatic 
secretions (EPS) that could be utilized as diagnostic 
and/or prognostic markers for prostate cancer 
(Principe et al., 2013). 
To be noted 
Roles of eEF1G in viral replication and 
pathogenesis  
eEF1G is an abundant cellular resource that seems to 
play an important role in the genomic replication, 
DNA synthesis, transcription and in the pathogenesis 
of a variety of viruses, such as HIV-1 and influenza 
A virus, by interacting with viral polymerases, 
structural and nonstructural proteins, and viral 
genome.  
When eEF1G is downregulated using a small 
interfering RNA (siRNA) also the viral replication is 
negatively affected and becomes more unstable and 
less efficient.  
However, the molecular interaction between the 
virus components and eEF1G or other translation 
factors remains to be determined (Sammaibashi et 
al., 2018; Dongsheng et al., 2013 ; Warren et al., 
2012).  
 Reduction of cell viability after causing the 
down-regulation by RNAi 
The knockdown of eEF1G subunit by a specific 
siRNA shown a slightly reduced cell viability/cell 
metabolism. In addition, was observed that its 
depletion can affect the expression of the eEF1B and 
eEF1D subunits (Cao et al., 2014).  
 Down-regulation of EEF1G in response to 
enterovirus 71 (EV71) infection.   
The transcriptomic and proteomic analyses of the 
rhabdomyosarcoma cells infected by enterovirus 71 
(EV71) has revealed a change in gene expression 
profiles of several genes in response to infection. In 
particular, was observed the down-regulation of 
EEF1G (Leong and Chow, 2006) although its 
significance remain unclear. 
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